Microbiology Devices; Reclassification of Human Immunodeficiency Virus Viral Load Monitoring Tests
Information
Type
Proposed Rule
Regulated products
Published
November 24, 2021
Last updated
November 24, 2021
Description
Document number 2021-25372. The Food and Drug Administration (FDA or the Agency) is proposing to reclassify human immunodeficiency virus (HIV) viral load monitoring tests, a postamendments class III device with the product code MZF, into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation along with special controls that the Agency believes are necessary to provide a reasonable assurance of safety and effectiveness for this device type. FDA is proposing this reclassification on its own initiative. If finalized, this order will reclassify this device type from class III (premarket approval) to class II (special controls) and reduce the regulatory burdens associated with these devices because manufacturers will no longer be required to submit a premarket approval application (PMA) for this device type but can instead submit a less burdensome premarket notification (510(k)) and receive clearance before marketing their device.
Tags
Organization
Country / Region
United States
License
Other (Public Domain)